NCT04946591

Brief Summary

Achievement of tumor-free resection margin with the largest possible remnant liver parenchyma is the major challenge in hepatic surgery. Therefore, perioperative tumor detection, anatomical mapping of liver segments and also nearby structures are vital to improve the short- and long-term surgical outcomes. Over last decades, several real-time methods have been introduced for this purpose. These methods are mostly based on the utilizing of traceable dyes, which are excreted into the biliary tract. With the advances in minimal invasive surgery and video technology, indocyanine green became the most used dye in this manner. It has been demonstrated that using indocyanine green, small liver tumors can be detected, which cannot be identified using conventional intraoperative methods. Based on the literature, the reported sensitivity of tumor detection using indocyanine green is ranging between 98%-100%, while conventional methods could not reach 90% sensitivity. Posthepatectomy bile leakage, as well as in- or outflow distributions due to the potential vascular reconstructions, are some of the most common complications that can occur especially after complex liver surgeries. Beside the abovementioned advantages of indocyanine green, several researchers have also shown the feasibility of indocyanine green to identify the intraoperative bile leaks and any in- or outflow distributions. Nevertheless, laparoscopic assisted liver surgery is technically challenging, mostly because of the restricted degrees of instrument movements, camera instability, and loss of depth perception. In particular, the loss of depth perception and inaccurate object localization can lead to intraoperative complications and a long learning curve. Advances in video technology, namely 4K ultra-high-definition imaging have been developed to reduce perioperative complications and to shorten the learning curve during laparoscopic liver surgery. This is the first prospective study evaluating the impact of indocyanine green imaging during 4K laparoscopic liver surgery on real-time tumor detection and surgical outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 19, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 1, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2021

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

September 2, 2025

Status Verified

August 1, 2025

Enrollment Period

2.9 years

First QC Date

June 19, 2021

Last Update Submit

August 25, 2025

Conditions

Keywords

Indocyanine greenTumor localizationBile LeakUltra-high-definition

Outcome Measures

Primary Outcomes (1)

  • Tumor localization

    One day

Secondary Outcomes (8)

  • Remnant liver venous drainage

    One day

  • Detection of resection plane

    One day

  • Rate of intraoperative bile leak

    One day

  • Rate of postoperative bile leak

    Three months

  • Resection margin

    One day

  • +3 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients with any type of liver tumor undergoing 4K laparoscopic hepatectomy using indocyanine green

You may qualify if:

  • Patient consent
  • Aged above 18 years
  • Undergoing any type of liver resections

You may not qualify if:

  • Unresectable liver tumors
  • Known indocyanine green allergy
  • Iodine allergy
  • Advanced cirrhosis (Child C)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Klinikum Saarbrücken

Saarbrücken, Saarland, 66119, Germany

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum, resected liver specimen

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the Department

Study Record Dates

First Submitted

June 19, 2021

First Posted

July 1, 2021

Study Start

August 1, 2021

Primary Completion

July 1, 2024

Study Completion

October 1, 2024

Last Updated

September 2, 2025

Record last verified: 2025-08

Locations